Network News
Key Points Abstract Donor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our study, we conducted a comprehensive screening of 217 older male volunteer donors with a history of extensive blood donation (>100 lifetime donations) to investigate the phenomenon of […]
read more
Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropismNew Collaborative Research Centre on Cancers of Blood-Forming Bone Marrow
Abstract Metastatic breast cancer remains largely incurable, partly due to our incomplete understanding of its intricate underlying mechanisms. Notably, inercellular communication mediated by small extracellular vesicles and particles (sEVPs) has emerged as a key feature of metastasis. While tumor-derived sEVPs have been extensively studied and are known to be pro-metastatic, the role of sEVPs from […]
read more
New Collaborative Research Centre on Cancers of Blood-Forming Bone Marrow
DFG funds research consortium at the Medical Faculty Heidelberg with around 15.8 million euros – A new Collaborative Research Centre based at the Medical Faculty Heidelberg is going to start at Heidelberg University. In its recent approval round, the German Research Foundation (DFG) decided to support CRC 1709 “Cellular Plasticity in Malignant Myeloid Diseases – […]
read more
Strategic alliance for rare diseases: RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe
Heidelberg/Germany, May 27, 2025. RHEACELL announced today that it has entered into an exclusive partnership agreement with the AOP Health Group, who will commercialize RHEACELL’s two stem cell products, EBESANAR® and AMESANAR®, in Europe, Turkey, Israel and the MENA region (Middle East and Northern Africa). RHEACELL retains full commercialization rights to EBESANAR® and AMESANAR® in […]
read more
Excellence Strategy: HITS researchers successful with two clusters on astrophysics and life sciences
How do stellar explosions or the evolution of galaxies influence our universe today? How can synthetic biology and specially designed cells aid in the protection of our immune system against infections and cancer? Tackling these research questions from different disciplines is the endeavor of two projects that have been selected as Clusters of Excellence in the […]
read more
Universität Heidelberg Successful With Three Applications for Clusters of Excellence
Funding for research projects at the highest level internationally In the context of the Excellence Strategy of the Federal and State Governments, Heidelberg University has been successful with three applications in the Cluster of Excellence funding line. According to the decision on selection announced today (Thursday 22 May 2025), not only will the existing cluster […]
read more
Peer Fischer elected Fellow of AIMBE
Peer Fischer, research group leader at the Max Planck Institute for Medical Research in Heidelberg and Professor at the Institute for Molecular Systems Engineering and Advanced Materials at Heidelberg University, has been elected a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). “The appointment is a great honor,” says Peer Fischer. ”I […]
read more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide
World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]
read more
EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research
More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]
read more
